Skip to content Skip to footer
Subscribe Now
Viewpoints_Jonathan Rigby
VIEWPOINTS

PharmaShots Interview: Janssen’s Andrew Greenspan Shares Insight About the New AGA Guidelines Recommending Stelara (Ustekinumab) as a First-Line Treatment Option in Crohn’s Disease

In an interview with PharmaShots, Andrew Greenspan, VP, Immunology Affairs at Janssen shared his views on the new AGA guidelines on the medical management of moderate-to-severe Crohn's disease and also highlighted about Janssen's efforts in improving the QoL of patients with CD The AGA guidelines assessed the overall benefit of each drug and also compared…
August 17, 2021

Read more

Viewpoints_Jan Wehkamp
VIEWPOINTS

PharmaShots Interview: Janssen’s Jan Wehkamp Shares Insight on the Data from UNIFI Study of Stelara Presented at ECCO

In an interview with PharmaShots, Jan Wehkamp, M.D., Vice President, Disease Area Leader, Gastroenterology at Janssen Research & Development shared his views on the data regarding the safety & efficacy of Stelara (ustekinumab) for UC patients, including long-term symptomatic & corticosteroid-free remission rates from the UNIFI study. Shots: The P-III UNIFI study evaluates the safety & efficacy…
August 9, 2021

Read more

Viewpoints_Mark Wildgust, Paolo Ghia & Paul Barr
VIEWPOINTS

PharmaShots Interview: Janssen’s Mark Wildgust along with Two Other Key Speakers Share Insights on Data Presented at ASCO 2021

In an interview with PharmaShots, Mark Wildgust, VP of Global Medical Affairs, Oncology at Janssen, Dr. Paolo Ghia, Division of Experimental Oncology at Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele and Paul Barr, Associate Professor of Medicine and Director of the Clinical Trials Office for the Wilmot Cancer Institute at University of Rochester…
July 19, 2021

Read more

Viewpoints_Dr. Jan Wehkamp and Dr. Bruce Sands
VIEWPOINTS

PharmaShots Interview: Janssen’s Dr. Jan Wehkamp and Icahn School of Medicine’s Dr. Bruce Sands Share Insights on the Data Presented at DDW 2021

In an interview with PharmaShots, Dr. Jan Wehkamp, M.D., Vice President, Gastroenterology Disease Area Leader at Janssen, and Bruce Sands, Dr. Burrill B. Crohn Professor of Medicine at the Icahn School of Medicine share their views on the data of Stelara and Tremfya presented at DDW 2021. Shots: Janssen presented the new data on Stelara (ustekinumab) and…
July 2, 2021

Read more

Viewpoints_Nan Li
VIEWPOINTS

PharmaShots Interview: Janssen’s Nan Li Shares Insights on the Data Presented at ISPOR 2021

In an interview with PharmaShots, Nan Li, Director of Access, Janssen Retina DAS shared her views on the attempts to quantify the economic burden of X-linked retinitis pigmentosa and achromatopsia. Shots: Janssen presented two posters on the economic burden and impact on people living with inherited retinal diseases X-linked retinitis pigmentosa (XLRP) and achromatopsia at ISPOR 2021…
June 21, 2021

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]